Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정혜경 | * |
dc.contributor.author | 홍지택 | * |
dc.date.accessioned | 2024-02-15T05:12:03Z | - |
dc.date.available | 2024-02-15T05:12:03Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 0031-6970 | * |
dc.identifier.other | OAK-34651 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/267841 | - |
dc.description.abstract | Purpose: To elucidate whether long-term proton pump inhibitor (PPI) users have an increased gastric cancer (GC) risk. Methods: We searched the 2009–2019 Korean National Health Insurance Services Database for patients aged > 40 years who claimed for Helicobacter pylori eradication (HPE) during 2009–2014. The GC incidence following a PPI exposure of > 180 cumulative defined daily dose (cDDD) and that following an exposure of < 180 cDDD were compared. The outcome was GC development at least 1 year following HPE. A propensity score (PS)–matched dataset was used for analysis within the same quartiles of the follow-up duration. Additionally, dose–response associations were assessed, and the mortality rates were compared between long-term PPI users and non-users. Results: After PS matching, 144,091 pairs of PPI users and non-users were analyzed. During a median follow-up of 8.3 (interquartile range, 6.8–9.6) years, 1053 and 948 GC cases in PPI users and non-users, respectively, were identified, with the GC incidence (95% confidence interval (CI)) being 0.90 (0.85–0.96) and 0.81 (0.76–0.86) per 1000 person-years, respectively. The adjusted hazard ratio (aHR) for GC with PPI use was 1.15 (95% CI, 1.06–1.25). Among PPI users, patients in the highest tertile for annual PPI dose showed higher GC development than those in the lowest tertile (aHR (95% CI): 3.87 (3.25–4.60)). GC–related mortality did not differ significantly between PPI users and non-users. Conclusion: In this nationwide analysis in Korea, where the GC prevalence is high, long-term PPI use after HPE showed a significant increase in GC, with a positive dose–response relationship. © 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | * |
dc.language | English | * |
dc.publisher | Springer Science and Business Media Deutschland GmbH | * |
dc.subject | Eradication | * |
dc.subject | Gastric neoplasms | * |
dc.subject | Helicobacter pylori | * |
dc.subject | Proton pump inhibitors | * |
dc.title | Risk of gastric cancer among long-term proton pump inhibitor users: a population-based cohort study | * |
dc.type | Article | * |
dc.relation.issue | 12 | * |
dc.relation.volume | 79 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1699 | * |
dc.relation.lastpage | 1708 | * |
dc.relation.journaltitle | European Journal of Clinical Pharmacology | * |
dc.identifier.doi | 10.1007/s00228-023-03580-7 | * |
dc.identifier.scopusid | 2-s2.0-85174507890 | * |
dc.author.google | Kim | * |
dc.author.google | Jong Wook | * |
dc.author.google | Jung | * |
dc.author.google | Hye-Kyung | * |
dc.author.google | Lee | * |
dc.author.google | Bora | * |
dc.author.google | Shin | * |
dc.author.google | Cheol Min | * |
dc.author.google | Gong | * |
dc.author.google | Eun Jeong | * |
dc.author.google | Hong | * |
dc.author.google | Jitaek | * |
dc.author.google | Youn | * |
dc.author.google | Young Hoon | * |
dc.author.google | Kwang Jae | * |
dc.contributor.scopusid | 정혜경(7403029723) | * |
dc.contributor.scopusid | 홍지택(57284959800;57206887950) | * |
dc.date.modifydate | 20240315130800 | * |